Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient

Patient from both gender, who had acute MI within recent 3 Weeks in LAD territory and would underwent PCI are eligible for this study. The bone marrow derived AC 133+ and MNC would be intracoronary injected to the patients during PCI procedure. The control group would be received just serum during PCI. The patient would be followed every month and at the end of 6th and 18thmonth the case and control groups will be evaluated by stress echo and Tc99 scan.

The totality of evidence from trials investigating autologous whole bone marrow infusion into patients following myocardial infarction supports the safety of this approach in terms of efficacy

Inclusion criteria

• BMI> 30
• First acute MI in LAD territory
• St elevation MI
• Ejection fraction: 20-45%
• at least two non - mobile or less mobile segment of left ventricular myocard.
• Successful PCI with stenting

Exclusion criteria

• Multivessel ceremony artery disease
• Pulmonary edema
• SBP < 80 mmHg
• Thrombocytopenia (PLT < 50, 000)
• INR > 2
• Hepatic failure or dysfunction
• Renal failure or dysfunction
• Positive HIV Ab/ HBC Ab/ HCV Ab/ HSV Ag
• Documental terminal illness
• Documental Malignancy
• Patient with sever coronary disease and unstability of vital sign
• History of leukopenia, Anemia, hepatic or renal dysfunction or malignancy